
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-02-01-2012
- Volume 24
- Issue 2
Evaluating Impurities in Drugs (Part I of III)
In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products.
By Kashyap R. Wadekar, Mitali Bhalme, S. Srinivasa Rao, K. Vigneshwar Reddy, L. Sampath Kumar and E. Balasubrahmanyam
To ensure the quality of APIs and finished drug products, impurities must be monitored carefully during process development, optimization, and process changeover. The isolation, characterization, and control of impurities in pharmaceutical substances are being reviewed with greater attention based on national regulatory and international guidelines. In Part I of this article, the authors examine the different types and sources of impurities with specific examples.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
over 14 years ago
News: FDA's Social Media Insightover 14 years ago
Head in the Cloudsover 14 years ago
Cliffhangerover 14 years ago
2012: A Good, Bad or Ugly Year for Servier?over 14 years ago
Understanding Gamma Sterilisationover 14 years ago
Decoding the Hype and Fear of Nanomedicinesover 14 years ago
Pointed Debate: Expert Views on Injectables



